Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN LEUNG

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1447328711
CMS profile
803106
Location
BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$11,339.06

78 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,251.00 2
Education $4,000.00 1
Food and Beverage $1,518.56 73
Travel and Lodging $569.50 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN LEUNG

NPI 1447328711 · CMS profile ID 803106

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447328711?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN LEUNG, NPI 1447328711, CMS profile ID 803106. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447328711?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JOHN LEUNG, NPI 1447328711, CMS profile ID 803106. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447328711?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JOHN LEUNG, NPI 1447328711, CMS profile ID 803106, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447328711?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

78 matching records · $11,339.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 78 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–78 of 78.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $12.5204/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834325087 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.5004/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849979629 CMS
ALK-Abello, Inc $13.8904/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809207559 CMS
Genentech USA, Inc. $20.1204/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835929945 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,850.0004/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820046183 CMS
GENZYME CORPORATION $21.7304/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843624701 CMS
CSL Behring $35.7404/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820251375 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.1904/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850036785 CMS
AstraZeneca Pharmaceuticals LP $23.8804/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834341923 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.0703/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820046179 CMS
AstraZeneca Pharmaceuticals LP $11.3303/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834347327 CMS
Braintree Laboratories, Inc. $27.9703/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805251429 CMS
CSL Behring $23.8603/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820251345 CMS
GENZYME CORPORATION $23.7003/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843624645 CMS
Genentech USA, Inc. $21.5103/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835929941 CMS
kaleo, Inc. $19.6303/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832122277 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.4503/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850404895 CMS
AstraZeneca Pharmaceuticals LP $33.6003/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834327299 CMS
AstraZeneca Pharmaceuticals LP $22.9002/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834337417 CMS
GENZYME CORPORATION $24.8502/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843624621 CMS
PFIZER INC. $14.3902/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833377401 CMS
GlaxoSmithKline, LLC. $23.2301/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802282265 CMS
AstraZeneca Pharmaceuticals LP $24.2601/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834347345 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $23.8601/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850422811 CMS
AIMMUNE THERAPEUTICS, INC. $18.9601/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850425591 CMS
GENZYME CORPORATION $16.5001/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843624613 CMS
Genentech USA, Inc. $23.9801/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835929939 CMS
CSL Behring $26.2401/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820251257 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $15,965.48 71
PY2020 $8,642.23 49
PY2021 $11,339.06 78
PY2022 $106,069.58 210
PY2023 $121,223.66 230
PY2024 $157,619.29 295
PY2025 $260,758.97 418

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,466.07 5
PY2025 Principal investigator $520,247.61 100
PY2024 Principal investigator $307,044.91 13
PY2023 Principal investigator $281,618.72 18
PY2022 Recipient $2,853.32 4
PY2022 Principal investigator $353,342.22 36
PY2021 Recipient $1,824.42 4
PY2021 Principal investigator $262,724.24 24
PY2020 Recipient $1,650.00 1
PY2020 Principal investigator $263,306.55 29
PY2019 Principal investigator $150,843.60 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

105 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $721.06 12/11/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184274568
Principal investigator 1 ABBVIE INC. $1,562.00 12/04/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202528946
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,825.12 12/04/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184269147
Principal investigator 1 SANOFI US SERVICES INC. $17,106.00 12/04/2025 Non-covered Recipient Entity
Boston Specialists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226122586
Principal investigator 1 ABBVIE INC. $8,155.65 11/26/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202525668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,124.04 11/25/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184264491
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,141.50 11/21/2025 Non-covered Recipient Entity
Boston Food Allergy Center Llc
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1235998524
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,871.70 11/20/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184263629
Principal investigator 1 ABBVIE INC. $349.70 11/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202524379
Principal investigator 1 ABBVIE INC. $5,718.55 11/07/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202523583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,921.74 11/07/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184258925
Principal investigator 1 ABBVIE INC. $201.10 11/04/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202521049
Principal investigator 1 SANOFI US SERVICES INC. $187.00 10/30/2025 Non-covered Recipient Entity
Boston Specialists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226128021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $721.06 10/29/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184253626
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,363.86 10/23/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184252574
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 10/23/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287603
Principal investigator 1 SANOFI US SERVICES INC. $7,813.00 10/17/2025 Non-covered Recipient Entity
Boston Specialists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226128017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,624.44 10/16/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184250633
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $392.00 10/15/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286773
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $553.00 10/15/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286861
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $392.00 10/15/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,429.00 10/15/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286865
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $553.00 10/15/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286867
Principal investigator 1 ABBVIE INC. $4,995.10 10/09/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202515175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,363.86 10/09/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184248946
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,232.78 10/08/2025 Non-covered Recipient Entity
BOSTON SPECIALISTS
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190307909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,650.24 10/03/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184244623
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $80.00 09/25/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223285901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,921.74 09/23/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184241612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,650.24 09/18/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184240444
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,429.00 09/17/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223285530
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,120.70 09/15/2025 Non-covered Recipient Entity
BOSTON SPECIALISTS
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190308326
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,765.22 09/12/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184236536
Principal investigator 1 ABBVIE INC. $12.00 09/05/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202510180
Principal investigator 1 SANOFI US SERVICES INC. $14,481.00 09/05/2025 Non-covered Recipient Entity
Boston Specialists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226128009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $721.06 09/04/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184235157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,642.80 08/26/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184230309
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $80.00 08/26/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284607
Principal investigator 1 SANOFI US SERVICES INC. $86.00 08/20/2025 Non-covered Recipient Entity
Boston Specialists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226128013
Principal investigator 1 ABBVIE INC. $794.55 08/18/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202504989
Principal investigator 1 ABBVIE INC. $139.35 08/18/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202504995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,363.86 08/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184228299
Principal investigator 1 SANOFI US SERVICES INC. $14,481.00 08/13/2025 Non-covered Recipient Entity
Boston Specialists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226128006
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,071.00 08/11/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,825.12 08/07/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184226121
Principal investigator 1 ABBVIE INC. $3,716.60 08/06/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202502454
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,194.48 08/01/2025 Non-covered Recipient Entity
BOSTON SPECIALISTS
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190308328
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 08/01/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223283347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,746.86 07/31/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184222810
Principal investigator 1 SANOFI US SERVICES INC. $193.00 07/23/2025 Non-covered Recipient Entity
Boston Specialists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226128001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,921.74 07/22/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184217713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,765.22 07/17/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184217038
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,071.00 07/16/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,442.12 07/10/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184214340
Principal investigator 1 ABBVIE INC. $3,311.60 07/08/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202497058
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,825.12 07/04/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184212821
Principal investigator 1 SANOFI US SERVICES INC. $14,481.00 07/02/2025 Non-covered Recipient Entity
Boston Specialists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226127996
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $903.38 06/24/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184210630
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,071.00 06/18/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281518
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,071.00 06/18/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,163.18 06/12/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184206217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,921.74 06/05/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184204143
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $63.00 06/04/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280592
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $55.00 06/04/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280594
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 06/04/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280596
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $51.00 06/04/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,921.74 05/28/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184198861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,921.74 05/15/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184194615
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,197.00 05/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279592
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $524.00 05/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279594
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,071.00 05/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279596
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,071.00 05/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,642.80 05/08/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184193731
Recipient Regeneron Pharmaceuticals, Inc. $322.61 05/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184119687
Recipient Regeneron Pharmaceuticals, Inc. $4,361.40 05/01/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 1184119689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $41,706.13 04/28/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184190639
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,186.44 04/23/2025 Non-covered Recipient Entity
LONG ISLAND REGIONAL ARTHRITIS AND OSTEOPOROSIS CARE, PC
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) No dispute reported 06/30/2026 1185544473
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,429.00 04/18/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278460
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $524.00 04/18/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278462
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,529.00 04/18/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278464
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,107.00 04/18/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278466
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $658.00 04/18/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278468
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $658.00 04/18/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278470
Principal investigator 1 ABBVIE INC. $5,000.00 04/04/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202474391
Principal investigator 1 SANOFI US SERVICES INC. $13,775.00 04/02/2025 Non-covered Recipient Entity
Boston Specialists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226127992
Recipient Regeneron Pharmaceuticals, Inc. $261.43 04/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184119683
Recipient Regeneron Pharmaceuticals, Inc. $264.88 04/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184119685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $650.00 04/01/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184180850
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,198.00 03/25/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184178868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,149.94 03/20/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184175018
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,197.00 03/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276469
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,197.00 03/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276471
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,471.00 03/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276483
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,487.00 03/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276485
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $524.00 03/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276487
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,429.00 03/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276489
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,529.00 03/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276491
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,107.00 03/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276493
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,471.00 03/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276495
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,487.00 03/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276497
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $524.00 03/14/2025 Non-covered Recipient Entity
BOSTON FOOD ALLERGY CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276499
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,954.00 02/12/2025 Non-covered Recipient Entity
Boston Specialists
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1235998518
Recipient Regeneron Pharmaceuticals, Inc. $255.75 02/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184119681
Principal investigator 1 AstraZeneca Pharmaceuticals LP $56,946.64 01/17/2025 Non-covered Recipient Entity
BOSTON SPECIALISTS
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) No dispute reported 06/30/2026 1185544471
Principal investigator 1 Celgene Corporation $19,363.00 01/13/2025 Non-covered Recipient Entity
Boston Food Allergy Center Llc
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222307137